Somerville, MA, United States of America

Martin Duplessis

USPTO Granted Patents = 28 (Patent Applications = 14)

EPO Patents = 12 (Patent Applications = 15)

Average Co-Inventor Count = 8.8

ph-index = 4

Forward Citations = 87(Granted Patents)

Location History:

Laval, CA (2011 - 2013)
Montréal, CA (2016)
Cambridge, MA (US) (2018 - 2019)
Watertown, MA (US) (2021)
Somerville, MA (US) (2015 - 2024)

Company Filing History:

12 out of 54

Constellation Pharmaceuticals, Inc.

patents

8 out of 32

C4 Therapeutics, Inc.

Boehringer Ingelheim International Gmbh

patents

5. 4 out of 4,942

Hoffmann-la Roche Inc.

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

28 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12486290 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-12-02),

2. 12486253 - Therapeutics for the degradation of mutant BRAF (2025-12-02),

3. 12441740 - N/O-linked degrons and degronimers for protein degradation (2025-10-14),

4. 12371442 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-07-29),

5. 12209091 - Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers (2025-01-28),

6. 12180225 - N/O-linked degrons and degronimers for protein degradation (2024-12-31),

7. 12048747 - Substituted piperidine Degronimers for Target Protein degradation (2024-07-30),

8. 11708354 - 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds (2023-07-25),

9. 11673902 - Isoindolinone and indazole compounds for the degradation of EGFR (2023-06-13),

10. 11459335 - N/O-linked Degrons and Degronimers for protein degradation (2022-10-04),

11. 11117890 - Substituted isoindole allosteric EGFR inhibitors (2021-09-14),

12. 10882848 - 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds (2021-01-05),

13. 10526287 - LSD1 inhibitors and uses thereof (2020-01-07),

14. 10358437 - Therapeutic compounds and uses thereof (2019-07-23),

15. 10308614 - Therapeutic compounds and uses thereof (2019-06-04),

Title: Unveiling the Inventive Mind of Martin Duplessis

Introduction: Martin Duplessis, a visionary inventor based in Somerville, MA, with a remarkable portfolio of 21 patents, is a true trailblazer in the field of innovative therapeutics. His groundbreaking work has significantly advanced the landscape of cancer treatment and inspired countless individuals to think outside the box.

Latest Patents: Among his latest patents, Martin Duplessis has introduced two revolutionary compounds to the pharmaceutical world. The first, 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds, serves as a selective allosteric inhibitor of T790M and C797S containing EGFR mutants, offering hope for more targeted cancer therapies. The second patent focuses on Isoindolinone and indazole compounds designed to degrade EGFR proteins, including mutant forms, paving the way for novel treatment strategies in oncology.

Career Highlights: Throughout his illustrious career, Martin Duplessis has made significant contributions to renowned companies such as Constellation Pharmaceuticals, Inc. and Genentech, Inc. His innovative spirit and dedication to pushing boundaries have led to groundbreaking advancements in the field of biopharmaceuticals.

Collaborations: Martin Duplessis has worked closely with esteemed colleagues like Christopher G Nasveschuk and Brian K Albrecht, fostering a collaborative environment where creativity and expertise converge to drive transformative inventions. These partnerships have been pivotal in bringing his visionary concepts to fruition and propelling the field of oncology forward.

Conclusion: In conclusion, Martin Duplessis stands as a shining example of an inventor who fearlessly challenges conventions and pursues bold ideas in the pursuit of a better future. His passion for innovation serves as a beacon of inspiration for aspiring inventors, urging them to dream big and make a lasting impact on the world.

This text is generated by artificial intelligence and may not be accurate.